Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HCK | P08631 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17826393 | 0.83 | — | — | |
| SCHEMBL12375388 | 0.80 | CYP1A2 (0.42) | QPCTQPCTLCYP1A2FTOTSHR | |
| SCHEMBL25589550 | 0.80 | LMNA (0.34) | TSHRENPP2MEN1KMT2A | |
| SCHEMBL31177244 | 0.80 | LMNA (0.34) | TSHRENPP2MEN1KMT2A | |
| SCHEMBL29956815 | 0.78 | NUDT1 (0.43) | CYP1A2METAP2KMT2A | |
| SCHEMBL1960426 | 0.78 | PLAU (0.32) | QPCTQPCTLCRHR1PLAUCYP1A2 | |
| SCHEMBL31416622 | 0.78 | CRHR1 (0.33) | QPCTQPCTLCRHR1PLAUCYP1A2 | |
| SCHEMBL29953563 | 0.77 | MEN1 (0.41) | CYP1A2TSHRGAAMEN1ALDH1A1 | |
| SCHEMBL30970996 | 0.77 | QPCT (0.42) | QPCTQPCTLCRHR1PLAUCYP1A2 | |
| SCHEMBL25392565 | 0.76 | KMT2A (0.37) | QPCTQPCTLCRHR1PLAUCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055371-A | Faster automated iterative C-C bond formation | 伊利诺伊大学评议会 | 2026-05-15 | — | — | CN | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260001884-A1 | Heterocycle compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-20250312345-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | UNIV YALE (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250270174-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| CN-120192323-A | Pyrrolidone-containing compounds | 正大天晴药业集团股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| WO-2003009689-A1 | METHODS AND COMPOSITIONS FOR TREATING FUNGAL INFECTIONS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002102800-A1 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-12-27 | — | — | WO | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-6420418-B1 | INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001012183-A1 | HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001884-A1 | Heterocycle compounds for the treatment of cancer | ADORA1, ADORA2A, ADORA3 | QPCT 3907/4885QPCTL 4593/4885CRHR1 418/4885 |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | QPCT 1460/4885QPCTL 4259/4885CRHR1 242/4885 |
| US-20250312345-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | ACE2, ACE, TMPRSS2 | QPCT 780/4885QPCTL 622/4885CRHR1 2419/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | QPCT 1893/4885QPCTL 4165/4885CRHR1 3688/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | QPCT 496/4885QPCTL 2048/4885CRHR1 4405/4885 |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | QPCT 2820/4885QPCTL 3880/4885CRHR1 1996/4885 |
| US-20250270174-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | QPCT 2794/4885QPCTL 4186/4885CRHR1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.